Effects of ONO-2506PO in Patients With Alzheimer's Disease

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00083421

Enrollment

647

Registered

2004-06-18

Start date

2004-06-30

Completion date

2007-07-31

Last updated

2012-06-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's Disease

Brief summary

The purpose of this study is to establish the presence of an effect of treatment with ONO-2506PO in patients with Alzheimer's Disease, based upon cognitive and global scales.

Interventions

DRUGONO-2506PO

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

50 Years to 90 Years

Healthy volunteers

Inclusion criteria

* Diagnosis of probable Alzheimer's Disease using NINCDS/ADRDA criteria * Standardized MMSE Score of 13 to 24 points (inclusive) * Modified Hachinski score equal or less than 4

Exclusion criteria

* Serious systemic disease that may preclude survival to study completion * Other illnesses that may include dementive features

Design outcomes

Primary

Measure	Time frame
Cognitive Function Scale	—
Global Function Scale	—

Secondary

Measure	Time frame
ADL Scale	—
Psychiatric Symptom Scale	—

Countries

Canada, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026